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Abstract
Systemic lupus erythematosus (SLE) encompass a 
broad spectrum of liver diseases. We propose here to 
classify them as follows: (1) immunological comorbili-
ties (overlap syndromes); (2) non-immunological co-
morbilities associated to SLE; and (3) a putative liver 
damage induced by SLE itself, referred to as “lupus 
hepatitis”. In the first group, liver injury can be ascribed 
to overlapping hepatopathies triggered by autoimmune 
mechanisms other than SLE occurring with higher 
incidence in the context of lupus (e.g. , autoimmune 
hepatitis, primary biliary cirrhosis). The second group 
includes non-autoimmune liver diseases, such as estea-
tosis, hepatitis C, hypercoagulation state-related liver 
lesions, hyperplasic parenchymal and vascular lesions, 
porphyria cutanea tarda, and drug-induced hepatotox-
icity. Finally, the data in the literature to support the 
existence of a hepatic disease produced by SLE itself, 
or the occurrence of a SLE-associated prone condition 
that increases susceptibility to acquire other liver dis-
eases, is critically discussed. The pathological mecha-
nisms underlying each of these liver disorders are also 
reviewed. Despite the high heterogeneity in the litera-
ture regarding the prevalence of SLE-associated liver 
diseases and, in most cases, lack of histopathological 
evidence or clinical studies large enough to support 
their existence, it is becoming increasingly apparent 
that liver is an important target of SLE. Consequently, 
biochemical liver tests should be routinely carried out 
in SLE patients to discard liver disorders, particularly in 
those patients chronically exposed to potentially hepa-
totoxic drugs. Diagnosing liver disease in SLE patients 
is always challenging, and the systematization of the 
current information carried out in this review is expect-
ed to be of help both to attain a better understanding 
of pathogenesis and to build an appropriate work-up 
for diagnosis.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The existence of liver disease associated with 
lupus itself, or increased susceptibility to concomitant 
liver diseases, either autoimmune or non-autoimmune 
ones, is still somewhat controversial, and difficult to 
diagnose. Data in the literature are scarce, and often 
based on case reports or clinical studies with limited 
patient size or histological evidence. The pros and cons 
to support the existence of such pathological entities, 
and the still preliminary studies on the mechanisms in-
volved, are critically discussed here. We concluded that 
liver is often a target of systemic lupus erythematosus, 
and biochemical liver tests should be systematically 
carried out in these patients.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease with variable clinical presentation, usually 
characterized by several immunological signs and symp-
toms[1-3]. It primarily affects women under 50 years of  
age, and is diagnosed on the basis of  presence of  at least 
4 out of  11 criteria identified by the American College of  
Rheumatology (ACR), either sequentially or simultane-
ously, namely malar rash, discoid rash, photosensitivity, 
oral ulcers, nonerosive arthritis, pleuritis or pericarditis, 
renal disorders (proteinuria or cellular casts), neurologic 
disorder (seizures or psychosis), hematologic disorder 
(hemolytic anemia, leukopenia or thrombocytopenia) and 
immunologic disorders (anti-DNA, anti-Sm or antiphos-
pholipid antibodies)[4-6].
The most common symptoms are fever, weight 
loss, and a general lack of  wellbeing and athralgia, while 
the most frequent signs are skin rashes. Biochemical 
exams typically present anemia, and increased rates of  
erythrosedimentation. Treatment includes nonsteroidal 
anti-inflammatory drugs (NSAIDs), corticoids, and im-
munomodulators. Death is generally caused by progres-
sive renal insufficiency, severe impairment of  the central 
nervous system, or multi-organic failure after systemic 
infection[4].
Even though, as above mentioned, alterations of  skin, 
joints and kidney, as well as of  the cardiovascular, hema-
tological and central nervous systems, are part of  the cri-
teria indicating morbidity, the liver can also be affected[1-5]. 
Although a true liver disease triggered by SLE itself  is a 
controversial issue, 25% to 50% of  patients may present 
alterations in the liver function tests (LFTs)[7]. The for 
and against data in the literature to support the existence 
of  the multiple associations of  SLE with liver disease will 
be discussed in detail in this review. Our literature inclu-
sion criteria limited the citation of  clinical cohort studies 
to those written in English language and published in 
peer reviewed journals; only very exceptional studies in 
other languages were included, when dealing with topics 
with extremely scarce information. The quotation stud-
ies in abstract form, when equivalent full papers were 
unavailable, was also very exceptional, and limited to peer 
reviewed, highly prestigious meetings.
PREVALENCE OF BIOCHEMICAL AND 
HISTOLOGICAL HEPATIC ALTERATIONS 
IN PATIENTS WITH SLE
Subclinical liver disease is common in SLE, and 25%-50% 
of  patients with lupus may develop abnormal liver func-
tion at some point[8,9]. The more common laboratory 
abnormalities associated with the different kinds of  liver 
disease related to lupus are summarized in Table 1. In 
addition, an overview of  the main biochemical and his-
tological findings reported in the literature is depicted in 
Table 2.
Hepatomegalia is detected in 12%-55% of  SLE pa-
tients, depending on the analyzed series[10]. In an original 
article by Mackay et al[11], the authors observed hepato-
megalia and/or alterations in LFTs in 19 SLE patients, 
normal liver biopsies in 6 cases, and minimal histological 
changes in another 11 ones (fatty liver, portal fibrosis, and 
mild to moderate portal infiltrate). Histological changes 
compatible with chronic hepatitis with progression to cir-
rhosis were confirmed in the remaining 2 patients. Similar 
findings were obtained by Polish researchers in a study 
of  18 SLE patients; whereas 5 of  them showed normal 
liver histologies, the other 13 ones showed only minimal 
hepatocellular changes[12]. These results do not agree with 
those observed by Runyon et al[13] who, in a retrospective 
review of  238 patients with SLE, observed hepatomega-
lia in 39% of  patients, splenomegaly in 6% and jaundice 
in 24%. Twenty one percent of  patients were defined as 
carriers of  liver disease based on abnormal liver histolo-
gies or, in some cases, elevation of  liver enzymes 2 times 
over the upper limit of  normal (ULN).
In the same study, liver histology of  33 patients 
showed steatosis (36%), cirrhosis and chronic active 
hepatitis (12%), hepatic granulomatosis, centrilobular 
necrosis (9%), and chronic hepatitis and microabscesses 
(6%). These findings were very challenging for the com-
mon view at the beginning of  80 s, and prompted other 
researchers to replicate these results. However, only one 
year after this report, Gibson et al[14] failed to reproduce 
such a high rate of  severe liver disease associated with 
SLE. They reported 55% of  patients with increase in 
transaminase levels among 81 patients with SLE, and 
identified SLE as the only explanation for this abnormali-
ty in 29% of  the cases. Histological analysis of  7 of  these 
patients revealed portal inflammation in 5, fatty liver in 1, 
and active chronic hepatitis in the remaining one. They 
also reported a 23% increase in the levels of  alanine ami-
notransferase (ALT)/aspartate aminotransferase (AST) 
and alkaline phosphatase (ALP) (≤ 2 times ULN), with 
a notable predominance among patients that presented 
active clinical signs of  SLE. All of  these abnormalities 
normalized with steroid treatment.
A prospective analysis by Miller et al[15] recruited 260 
patients with SLE that were followed up for a 12-mo 
period. In the follow-up examinations, liver enzymes lev-
els were high in 23% of  them. Clinical liver disease was 
observed in only 2% of  the cases, while causes for liver 
compromise unrelated to SLE were verified in only 15% 
of  the cases. No specific cause for liver disease other 
than SLE could be identified in 8% of  the patients. The 
histological analysis carried out on 14 patients found only 
minimal and non-specific changes. It is noteworthy that 
the increase in transaminase levels in 12 out of  15 pa-
tients appeared concomitantly with lupus activity.
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A much lower frequency of  liver abnormalities was 
reported by Fox et al[16] in a retrospective cohort of  200 
patients, where an increase of  liver enzymes was docu-
mented in only 2.5% of  the cases. These biochemical 
changes were associated with liver clinic manifestations 
only in few cases, and had no relationship with plasmatic 
ribosomal-P antibodies.
Very interesting findings were published by Matsu-
396 June 27, 2014|Volume 6|Issue 6|WJH|www.wjgnet.com
Table 1  Biochemical and histological liver abnormalities in  systemic lupus erythematosus  patients according to different reports in 
the literature
Ref. Study type Patients NO. of patients with biochemical Liver histological findings
with SLE alterations and alteration types
Mackay et al[11] Retrospective   19 (n = 19)
↑ AST, ALT
Minimal changes, portal fibrosis, steatosis, 
inflammation (n = 11)
Normal (n = 6)
Chronic hepatitis (n = 2)
Chwalińska-Sadowska et al[12] Retrospective   18 NA Minimal changes (n = 13)
Normal (n =5)
Runyon et al[13] Retrospective 238 (n = 124)
↑ AST, ALT, total bilirubin, ALP, 
GGT, LDH (≥ 2 × ULN)
(n = 33)
Steatosis (n = 12)
Others: cirrhosis, chronic hepatitis, granulomatosis, 
chronic hepatitis, steatosis, cholestasis, centrilobular 
necrosis
Gibson et al[14] Retrospective   81 (n = 64)
↑ AST, ALT, ALP
(n = 7)
Portal inflammation (n = 5)
Steatosis (n = 1)
Chronic hepatitis (n = 1)
Miller et al[15] Prospective 260 (n = 84)
↑ AST, ALT, ALP
Minimal changes (n = 14)
Matsumoto et al[17] Retrospective   73 NA Hepatic arteritis (n = 11)
Steatosis (n = 53)
RNH (n = 5)
Viral hepatitis (n = 2)
SLE-PBC overlap syndrome (n = 1)
SLE-AIH overlap syndrome (n = 1)
Luangjaru et al[9] Retrospective 225 (n = 80)
↑ AST, ALT (≤ 4 × ULN)
NA
Chowdhary et al[7] Retrospective 192 (n = 40)
↑ AST, ALT
HCV (n = 3)
Steatosis (n =5)
SLE-AIH overlap syndrome (n = 4)
SLE-PBC overlap syndrome (n = 3)
Cryptogenic cirrhosis (n = 1)
Piga et al[3] Retrospective 242 (n = 59)
↑ AST, ALT (≥ 2 × ULN)
NA
Her et al[138] Retrospective 141 (n = 46)
↑ Total bilirubin, AST, ALT, LDH, 
ALP
(≥ 2 × ULN)
NA
Huang et al[90] Retrospective       1533 (n = 134)
↑ AST, ALT (≥ 2 × ULN 
during 2 yr)
Chronic Hepatitis (n = 6)
Minimal changes (n = 4)
Normal (n = 3)
Zheng et al[2] Retrospective 504 (n = 47)
↑ Total bilirubin (13%), ALT (98%), 
ALP (42%), GGT (49%)
(n = 10)
Portal blood cell infiltration (n = 8)
Hydropic degeneration (n = 8)
Steatosis (n = 2)
Mild cholestasis (n = 2)
Focal necrosis (n= 1)
Nodular cirrhosis (n = 1)
Takahashi et al[18] Prospective 206 (n = 123)
↑ AST, ALT (99%)
↑ ALP and GGT (81%)
(n = 25)
Lupus hepatitis (n = 16):
Unspecific reactive hepatitis (88%)
Active hepatitis (12%)
SLE-AIH overlap syndrome (n = 6):
Interface hepatitis (100%)
Cirrhosis (33%)
SLE-PBC overlap syndrome (n = 3)
SLE: Systemic lupus erythematosus; ULN: Upper limit of normal; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LDH: Lacto dehy-
drogenase; ALP: Alkaline phosphatase; GGT: Gamma glutamil transferase; HCV: Hepatitis C virus; PBC: Primary biliary cirrhosis; AIH: Autoimmune 
hepatitis.
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with exacerbations of  the lupus disease, which returns to 
normal values after corticosteroid therapy[2,14,15].
May be a part the confusion begun in the early 50’s, 
when AIH was wrongly referred to as “lupoid hepatitis”
[11]. Subsequent studies added more confusion when no 
serology was available to rule out overlapping chronic 
viral diseases [hepatitis C virus (HCV), hepatitis B virus 
(HBV), cytomegalovirus, etc.] in SLE patients with hyper-
transaminasemia.
In the early 80’s, Runyon et al[13] reactivated the debate 
publishing a very controversial study describing both 
a “canalicular cholestasis” profile and SLE-related cir-
rhosis as diseases triggered by lupus itself. As mentioned 
before, the sample analyzed in this study consisted of  33 
lupus patients presenting different types of  liver damage 
that were documented by liver biopsy, namely steatosis, 
chronic hepatitis, hemochromatosis, granulomatose hepa-
titis, cholestasis and cirrhosis. Serological and virological 
markers to rule out hepatitis C did not exist at this time.
As was also stressed above, another condition that is 
needed to rule out among SLE patients with hypertrans-
aminasemia is an overlap with AIH, which represents a 
separate disease from lupus, both because of  its distinct 
pathogenic mechanism (specific organ) and its distinctive 
biochemical, serological, and histological characteristics 
that allow for a clear differentiation.
Hypergammaglobulinemia, autoantibodies [antinucle-
ar antibody (ANA), antismooth muscle antibody (ASMA), 
anti-liver-kidney microsome antibodies], a histological 
profile characterized by piecemeal necrosis (interface 
hepatitis), and a rich plama cells infiltrate are highly dis-
tinctive aspects of  AIH. On the other hand, if  a lupus 
patient presents evidence of  progressive non-autoim-
mune chronic hepatitis characterized by persistent severe 
inflammatory damage, we need to consider first other 
probable diagnosis of  chronic liver injury, such as hepa-
titis B or C, or other autoimmune diseases overlapping 
with lupus. The discrimination is further complicated by 
the fact that liver histopathological features in patients 
with lupus hepatitis are miscellaneous and non-specific, 
similar to those in other liver diseases. It is therefore im-
portant, before diagnosing lupus hepatitis, to rigorously 
rule out other liver diseases, including drug-induced liver 
injury, alcohol liver disease, viral hepatitis (hepatitis A, 
B, C, D, E, Epstein-Barr virus or cytomegalovirus), and 
other autoimmune-associated liver diseases [AIH, PBC, 
primary sclerosing cholangitis (PSC)].
A recent study by Zheng et al[2] based on this strict 
discrimination criteria reported a 9.3% lupus hepatitis 
incidence among 504 SLE patients evaluated. However, 
the prevalence reported in the literature is rather variable, 
with both lower[4,8,17,19] and higher[14,18,20] rate values.
Zheng et al[2] also reported that the prevalence of  lupus 
hepatitis in patients with active SLE was higher than those 
with inactive SLE (11.8% vs 3.2%). The patients with 
lupus hepatitis mostly showed mild to moderate eleva-
tions of  serum transaminase levels, though 6 patients had 
jaundice as the predominant feature. ALP and Gamma 
moto et al[17], who analyzed liver histology of  73 patients 
with SLE. They identified fatty liver as the major feature 
in 72% of  the cases, while nodular regenerative hyper-
plasia, viral hepatitis, primary biliary cirrhosis (PBC), and 
autoimmune hepatitis (AIH) were identified as the main 
cause of  liver disease only in few cases (6.8%, 4.1%, 2.7%, 
and 2.7%, respectively).
Finally, Takahashi et al[18] reported recently that liver 
dysfunction was apparent in 123 (59.7%) out of  206 
patients. They identified different causes of  liver dys-
function as follows: induced by drug (30.9%), caused 
by SLE itself  (28.5%), fatty liver (17.9%), AIH (4.9%), 
PBC (2.4%), cholangitis (1.6%), alcohol (1.6%), and viral 
hepatitis (0.8%). The liver dysfunction tends to be mild, 
except when caused by AIH.
From the studies reported above, it is readily appar-
ent that the published data linking liver diseases with SLE 
during the last four decades are highly heterogeneous, 
and that a high number of  cases lack adequate histologi-
cal documentation.
LIVER DISEASES IN THE SLE CONTEXT
The frequent association between SLE and LFT altera-
tions may be accounted for by three possibilities, namely: 
(1) the existence of  some kind of  liver parenchymal in-
jury associated with SLE alone, often referred to as “lupus 
hepatitis”; (2) the occurrence of  an overlap syndrome by 
which SLE shows additional features of  another autoim-
mune liver disease; and (3) the concurrency of  comor-
bility of  SLE with a non-autoimmune hepatopathy, e.g., 
drug-induced liver damage, viral hepatitis or thrombotic 
liver disease, among others.
Lupus hepatitis
Although it is still a controversial issue, there is compiling 
evidence in the literature that lupus itself  is not associ-
ated with a specific, severe and progressive liver injury. 
However, several authors have pointed a role for SLE in 
triggering an often subclinical hepatopathy, referred to 
as “lupus hepatitis”. They described this disease as an as-
ymptomatic hypertransaminasemia frequently associated 
Table 2  Laboratory abnormalities in the different hepatic 
manifestations associated with systemic lupus erythematosus
Hepatic alteration Laboratory abnormalities
Hepatic steatosis GGT, ALT/AST
Viral hepatitis ALT, AST, HCV, cryoglobulinemia
Toxic hepatitis ALP, GGT, AST/ALT, bilirubin
Nodular regenerative hyperplasia ALT, AST, thrombocytopenia
Primary biliary cirrhosis ALP, GGT, AMA
Autoimmune hepatitis ANA, ASMA, gammaglobulin
Hepatic venous thrombosis Antiphospolipidic antibodies
Lupus hepatitis Anti-ribosomal P autoantibodies
AMA: Antimitocondrial antibody; ANA: Antinuclear antibody; ASMA: 
Antismooth muscle antibody; GGT: Gamma glutamil transferase; ALP: 
Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate 
aminotransferase. 
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glutamil transferase elevations were far less frequent. Only 
12.8% had liver injury-related clinical manifestations. Lu-
pus hepatitis responds well to moderate to high doses of  
corticosteroids[3].
In patients suspected to have lupus hepatitis, it has 
been often reported a correlation between hepatic en-
zymes abnormalities and autoantibodies to ribosomal 
P proteins (anti-ribosomal P), a highly specific marker 
for SLE[19,21,22]. Indeed, several reports suggest that SLE-
related hepatitis may be associated with, or even caused 
by this autoantibody.
Anti-ribosomal P occurs in 12%-16% of  patients 
with lupus[21-24], although this proportion increased to 
30% when more sensitive methods were employed [en-
zyme-linked immunosorbent assay (ELISA) based upon 
the combination of  different ribosomal-P antigens], 
with Caucasian ethnicity having lower values[25]. The 
proportion of  serum anti-ribosomal P occurrence raised 
to 44% among SLE patients with liver dysfunction and, 
from them, 70% had SLE-associated hepatitis, a far 
higher value as compared with SLE patients suffering 
from other hepatic alterations, such as fatty liver (29%), 
drug-induced hepatitis (17%), or SLE-AIH overlap syn-
drome (20%)[26]. Furthermore, Koren et al[27] reported 
the development of  chronic active hepatitis in a patient 
with SLE followed several months later by the appear-
ance of  high serum levels of  anti-ribosomal P antibod-
ies, and suggested a possible causal relationship. As for 
the mechanism explaining this causal relationship, anti-
ribosomal P positive sera from SLE patients were found 
to react strongly “in vitro” with a polypeptide antigeni-
cally related to a 38 kD ribosomal P0 protein present on 
the plasma membrane of  hepatoma cells[28], thus further 
strengthening the possibility that anti-ribosomal P anti-
bodies could be directly detrimental in lupus patients by 
inducing hepatocellular lysis, and further transaminase 
release. Finally, anti-ribosomal P antibodies up-regulate 
the expression of  proinflammatory cytokines by periph-
eral monocytes in SLE, which may be a contributing fac-
tor for hepatitis development[29].
Given that auto-antibodies directed against eukaryotic 
P proteins are highly specific to SLE, they can be used as 
diagnostic markers of  the disease. However, there is no 
standard methodology for its detection and titration in 
clinical practice. The plasma titers of  this antibody often 
fluctuate in relation to lupus activity, and were formerly as-
sociated with neuropsychiatric kidney and liver failure[22,26].
Several isolated cases have been reported of  asso-
ciation of  anti-ribosomal P antibody occurrence with 
hepatitis, and also with kidney failure[27,30]. However, it 
was Arnett et al[19] the first to report this association in a 
cohort study in 1995. They found lupus-related hepati-
tis in 3% of  131 lupus patients in a retrospective study 
that analyzed the hepatic manifestations of  SLE. The 
clinical outcome for these patients was variable, from a 
minimum, subclinical increase of  transaminases to acute 
hepatitis and overt liver failure. Unfortunately, histologi-
cal studies were not carried out in this study to correlate 
the degree of  liver injury associated with lupus hepatitis 
and the levels of  anti-ribosomal P antibodies.
Although these lines of  evidence link anti-ribosomal 
P antibodies to liver damage in SLE patients, the as-
sociation is still highly controversial. For example, lack 
of  a clear association between lupus hepatitis and anti-
ribosomal P levels was reported in a recently published 
retrospective study of  73 patients with SLE, where 12 of  
them (16%) were reported to have lupus hepatitis. In this 
group, 6 patients had a concurrent liver involvement with 
the diagnosis of  SLE, and it occurred later during an ex-
acerbation of  the disease in the remaining 5 patients[19]. 
Clinical manifestations were as follows: hepatomegaly (n 
= 4), jaundice (n = 4), abdominal pain (n = 3), ascitis (n 
= 2), portal hypertension (n = 1), and hepatic failure with 
encephalopathy (n = 1). Despite elevated liver enzymes 
were noted in 11 cases and cholestasis in 8 ones, the pres-
ence of  anti-ribosomal P antibodies was observed only 
in one case, and therefore an association between lupus 
hepatitis and any kind of  specific antibody could not be 
documented. Liver biopsy in 5 patients showed chronic 
active hepatitis in 3 cases, chronic hepatic granulomas 
in 1 case, and nonspecific inflammation in another one. 
Although the authors showed clear evidence of  immu-
nosuppressive therapy response in most patients, liver bi-
opsy was performed in less than half  of  them, and their 
description was not detailed enough to clearly differenti-
ate lupus hepatitis from AIH.
In part, disagreements on the association between 
anti-ribosomal P antibody and lupus hepatitis can be ex-
plained by different features of  the studied populations 
(e.g., ethnicity), environmental factors affecting autoanti-
gen expression, and distinct degrees of  sensitivity/speci-
ficity of  the methods used to detect anti-ribosomal P 
antibodies. Usually, associations between anti-ribosomal 
P antibody levels and hepatitis were investigated by using 
not well-standardized, or even “in-house” immunological 
methods[19,26]. Unfortunately, large cohort studies where 
lupus hepatitis or other SLE hepatic manifestations have 
been reliably documented, and where well-standardized, 
high sensitivity/specificity immunological methods are 
employed to detect anti-ribosomal P antibodies (e.g., 
those using a mixture the ribosomal P antigens P0, P1, and 
P2), are lacking, and we eagerly await them to confirm or 
deny the existence of  this association. 
To complicate the picture further, Calich et al[31] re-
ported recently the presence of  anti-ribosomal P anti-
bodies in patients having AIH not associated with lupus 
(9.7%; 9/93), and suggested that this antibody predicts 
worse prognosis of  the disease, with follow-up data 
showing higher prevalence of  cirrhosis in anti-ribosomal 
P antibody-positive AIH patients (100%, 7/7). This find-
ing suggests that anti-ribosomal P antibodies can be in-
volved in the pathogenesis of  other hepatic autoimmune 
diseases, apart from lupus hepatitis. The debate is still 
open, and it is apparent that we need more data to sup-
port the role and impact of  anti-ribosomal P antibodies 
in both SLE and AIH pathogenesis.
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Overlap of SLE with autoimmune liver diseases (overlap 
syndromes)
The existence of  overlap syndromes linking SLE with 
other autoimmune liver diseases is matter of  controver-
sies since, again, the data in the literature are scarce.
According to the so called “theory of  the mosaic of  
autoimmunity”[32], each of  these associations may repre-
sent a particular variant of  a major underlying autoim-
mune disease, which can shows up under the form of  
multiple autoimmune liver diseases coexisting in the same 
patient. Other good examples of  such variants are more 
typical hepatic overlap syndromes, such as AIH-PBC and 
AIH-PSC[33].
Although AIH or PBC are rare among SLE patients 
taken as a whole[34], the co-existence of  SLE with either 
of  these liver diseases is not uncommon among the sub-
group of  SLE patients with liver enzyme abnormalities. 
Chowdhary et al[7] reported a strong association between 
SLE and autoimmune liver disease. They found that 8 
out of  40 SLE patients (20%) were AIH carriers, while 6 
(15%) showed evidence of  PBC.
In another study by Efe et al[35], 36 SLE patients out 
of  147 (25%) had liver enzyme abnormalities, and 7 of  
them (4.7%) had SLE associated with another autoim-
mune liver disease. The rate rose to 19.4% when the sub-
set of  SLE patients having HLTs altered was considered 
and, from them, 72.3% fulfilled the criteria for AIH pro-
posed by the International Autoimmune Hepatitis Group. 
The therapy with ursodeoxycholic acid, prednisone, im-
munosuppressive thiopurine analogs, or a combination 
of  them, was successful in these patients.
SLE-AIH overlap syndrome
There have been very few reported cases of  AIH associ-
ated with SLE. It is therefore apparent that AIH and SLE 
overlap syndrome is a rare condition, although its exact 
incidence is unclear.
Oka et al[36] reported 5 (3%) patients with AIH in an 
analysis of  162 cases of  SLE meeting the ACR criteria. 
Similar findings were documented by Tamai et al[37], who 
found 10% of  AIH in a series of  21 SLE cases.
There is evidence in the literature suggesting that SLE 
and AIH are different diseases, even when clinical, bio-
chemical and serological characteristics may show over-
lapping features, such as the presence of  polyarthralgia, 
hypergammaglobulinemia, and positive ANA, ASMA and 
anti-ribonucleoprotein[38]. In these cases, liver histology is 
the decisive tool to define diagnosis. The presence of  cir-
rhosis or periportal hepatitis associated with lymphocytes 
and plasma cell infiltration, as well as rosette formation 
of  liver cells, tips the scales towards AIH. On the other 
hand, the presence of  mainly lobular and occasionally 
portal inflammation with a paucity of  lymphoid infiltrates 
is more compatible with SLE. Finally, a mixed histologi-
cal pattern is expected in SLE-AIH syndrome, displaying 
chronic hepatitis with severe inflammatory activity char-
acterized by focal necrosis of  hepatic cells, erosion of  the 
lobular limiting plate, periportal hepatitis, infiltration by 
lymphocytes and plasma cells, presence of  fibrosis in the 
portal areas and, eventually, cirrhosis[39,40]. In this context, 
positivity for anti-Sm antibodies, which are highly specific 
though relatively insensitive to SLE, helps to confirm 
SLE-AIH overlapping. In addition, presence of  antibod-
ies to double-stranded (ds) DNA, another hallmark of  
SLE, were found to be associated with poorer immediate 
response to corticosteroid treatment in AIH[41].
SLE-PBC overlap syndrome
PBC is also an autoimmune liver disease, and overlapping 
with PBC is likely to some extent. However, the co-ex-
istence of  PBC and SLE is the subject of  few reports in 
the literature, mostly based upon single case reports[42,43]. 
A large-scale study reported that, among 1032 PBC pa-
tients, 27 (0.03%) had also SLE[44]. Interestingly, anti-
dsDNA and anti-ribosomal-P antibodies, two serological 
markers of  SLE, were detected in 22% and 5%, respec-
tively, of  “pure” PBC patients[45].
SLE-PBC association has been documented mainly 
in patients with arthritis, polyserositis, and high titers 
of  anti-native DNA and anti-mitochondrial antibodies 
(AMAs), two pathognomonic signs of  SLE and PBC, re-
spectively. Again, PBC can appear in a pre-existing lupus 
as an expression of  an immunological disorder that has 
not been totally clarified. Osteopontin, a soluble ligand 
with pleomorphic immunologic activities that plays an 
important role in inflammation and immunity, may be a 
link. Osteopontin was reported to be highly expressed in 
the murphy roths large/lpr mouse[46], a well recognized 
models of  SLE, and it is involved as a chemoattractant 
cytokine in the recruitment of  macrophages and T lym-
phocytes in the liver granulomas in PBC[47]. Interestingly, 
Han et al[48], in a large cohort of  1141 SLE patients, con-
firmed the association between osteopontin and SLE.
Finally, AIH-PBC overlap syndrome has been reported 
to occur in 2.8% of  SLE patients, suggesting the associa-
tion of  not only two but even three autoimmune diseases 
(SLE-AIH-PBC overlap syndrome)[49]. Furthermore, anti-
dsDNA antibodies, which are known to be strongly as-
sociated with SLE, were detected in 60%[50] or 56%[51] of  
patients with AIH-PBC overlap syndrome.
SLE-PSC overlap syndrome?
Evidence for SLE-PSC overlap syndrome is limited at 
best, and only based upon few case reports[52-55]. Wheth-
er this clinical association indicates that some immune 
disorders are common to the two autoimmune diseases 
or whether they were casual associations remains to be 
ascertained.
Association of SLE with non-autoimmune liver diseases 
(comorbidity)
SLE patients often present comorbidity with a number 
of  non-autoimmune liver diseases. In many cases, the 
prevalence of  the concomitant hepatopathy is higher 
when associated with SLE than alone, indicating either 
increased susceptibility to the concomitant disease trig-
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gered by SLE or vice versa.
Association of SLE with hepatitis C
Autoimmunity and viral infections are closely associated 
fields, and viruses have been proposed as a likely etiologi-
cal, contributing or even triggering factor of  systemic 
autoimmune diseases[56]. This holds true also for SLE, 
since some hypotheses have identified viruses as potential 
agents that trigger SLE, with a close relationship to the 
pathogenic mechanism of  damage[57].
Very little association has been found between SLE 
and patients infected with HCV. Most reports linking the 
two diseases refer to the presence in these patients of  
skin lesions, anti-DNA antibodies, hypocomplementemia 
and cryoglobulinemia[57].
In a study of  134 patients carrying SLE, the presence 
of  anti-HCV antibodies (ELISA) was observed in 18 pa-
tients (13%), while the prevalence among voluntary blood 
donors in a large number of  countries ranges from 0.5% 
to 2%, only. Active infection by HCV was confirmed in 
15 (11%) of  the patients with positive ELISA HCV[57]. 
Similar results were obtained in other study where HCV 
was detected in 4 out of  40 SLE patients (10%), whereas 
prevalence among voluntary blood donors was only of  
0.13%[58]. Steroid therapy in these patients did not seem 
to alter the HCV course[59]. Whether this reflects a true 
higher HCV prevalence associated to SLE or it is a mere 
consequence of  the multiple admissions and blood trans-
fusions that these patients are subjected remains to be 
defined. Large-scale studies avoiding these potential bias 
are awaited.
It should be on the other hand acknowledged that 
HCV chronic infection is associated with different bio-
chemical and histological manifestations of  autoimmuni-
ty that, in certain cases, can mimic SLE[60]. Different types 
of  non-organ-specific autoantibodies can be detected in 
chronic hepatitis C (e.g., anti-soluble liver antigen, ANA, 
AMT, rheumatoid factor) and, less frequently, it is associ-
ated with low anti-DNA titers; for example, about 20% 
with hepatitis C patients are ANA positive[61]. In addition, 
chronic hepatitis C can occur with cryoglobulinemia, 
which can lead to a wrong SLE diagnosis, due to the 
simultaneous occurrence of  ANA, dermathological and 
renal lesions and plaquetopenia; this is why, in patients 
suspected to have SLE, HCV infection must be excluded 
using routine anti-HCV serology and, HCV-RNA tests. 
Several factors lead to the production of  autoantibod-
ies in HCV patients, including leakage of  intracellular 
components due to the persistent destruction of  infected 
cells[61], the molecular mimicry between HCV and auto-
antigens[62], and the functional abnormalities of  infected 
B lymphocytes, with production of  excessive autoanti-
bodies and cryoglobulins[63].
Fukuyama et al[64] reported for the first time in the 
literature the development of  an SLE profile after inter-
feron α-2 therapy. There are over 10 currently published 
cases that link the use of  interferon to treat hepatitis C 
with the appearance of  SLE associated with different lev-
els of  severity, including one patient with a serious lupus 
cardiomyopathy that threatened his/her life.
Although chronic infection with HCV can induce 
clinical and serological changes that can be confused 
with an autoimmune disease (arthritis, nephropathy, and 
cytopenias), the appearance of  malar rash, discoid lesion, 
photosensitivity, neurological damage, high titers of  ANA 
or anti-DNA antibodies, and anti-Sm antibody occur-
rence usually constitute sufficient evidence to diagnose 
SLE[7].
The clinician must consider three situations in the 
context of  a HCV antibody in a patient with SLE, name-
ly: (1) it may be a false positive HCV ELISA test due 
to the high levels of  autoantibodies that are frequently 
presented in SLE patients; (2) could be true association 
between SLE and hepatitis C; and (3) HCV can trigger 
the occurrence of  low levels of  ANA and/or anti-DNA, 
associated with cryoglobulinemia, without typical skin 
changes[19].
One common complication of  SLE patients is the so 
called “lupus nephritis”, and HCV may play a role. Few 
cases of  lupus nephritis coexisting with HCV infection 
have been described[65,66]. Although speculative, it is likely 
that the altered immune response in SLE facilitates HCV 
infection, and vice versa, that different autoantibodies as-
sociated with HCV infection facilitate the development 
of  lupus nephritis due to formation of  immune complex 
deposits in the kidneys. The increase in serum B-lympho-
cyte activating factor levels in chronic HCV patients with 
infection and SLE may be a contributing factor, by rein-
forcing B-cell activation and autoantibody production[67].
Association of SLE with hypercoagulation state-related 
liver lesions
SLE patients have a high potential to develop throm-
boembolic disorders that can impact on hepatic circu-
lation[68]. The frequent presence of  anti-phospholipid 
antibodies among these patients can include thrombotic 
manifestations in different territories of  the splachnic 
vasculature, both in arterial and venous areas (thrombosis 
of  the hepatic artery, portal thrombosis, and Budd-Chiari 
syndrome)[69]. Portal hypertension profiles and esopha-
geal varices have also been reported in several cases as 
secondary events linked to thrombosis of  the portal vein, 
triggered by the presence of  anti-cardiolipin antibodies[10].
Regenerative nodular hyperplasia (RNH), which fol-
lows hepatic vein thrombosis and hepatic circulation 
disorders, has also been reported in association with SLE 
(Figure 1)[70]. The pathogenesis of  RNH complicating 
SLE is believed to be related to vasculitis of  intrahepatic 
arteries, leading to secondary portal venous obliteration 
and thrombosis of  the adjacent portal veins[1]. Alterna-
tively, occlusion of  intrahepatic small vessels may result 
from coagulopathy in patients with associated anti-
phospholipid syndrome[9]. It has been suggested that anti-
phospholipid antibodies play a pathogenic veno-occlusive 
role in the pathogenesis of  RNH[71].
One of  the most attractive theories regarding RNH 
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origin involves the storage of  immune complexes in small 
caliber intrahepatic vessels, and the further appearance 
of  obliterative venopathy[70]. The liver histology pattern is 
characterized by the presence of  multiple hepatic nodes 
that do not have their own walls and that, in the absence 
of  fibrosis, are circumscribed by thin bands formed by 
the flattening of  hepatocyte columns emulating thin fi-
brous membranes. This condition is another component 
of  a long list of  diseases linked to non-cirrhotic portal 
hypertension. It is often associated with hematological 
diseases and various conditions that typically present 
systemic impairment (rheumatoid arthritis, CREST syn-
drome, Felty’s syndrome)[72]. Another theory suggests 
that the association between RNH and anti-phospholipid 
antibodies is due to the cellular regeneration process that 
begins in the liver to maintain its functional capacity after 
the ischemic injury induced by these antibodies in the he-
patic microcirculation[68].
RNH should be suspected in any patient with both 
SLE and portal hypertension in the absence of  cirrho-
sis. The diagnosis can be established after a liver biopsy. 
Due to the large size of  the regenerative nodes, there is 
a chance for the needle to be positioned in an area with 
no histological damage, which accounts for sampling er-
ror. When RNH is to be diagnosed, laparoscopic wedge 
biopsy is a safe and efficient way to obtain enough tissue 
to preserve the hepatic architecture required for analysis, 
avoiding in turn the morbidity associated with an unnec-
essary open resection[73].
Hepatic imaging of  RNH shows several additional 
findings, including focal nodular hyperplasia (FNH), hepa-
tocellular adenoma, regenerative nodules, and liver meta-
static disease. Computed tomography can show normal 
liver, numerous small nodules, or larger coalesced nodules 
spanning several centimeters. On nuclear medicine imag-
ing, these lesions may take up sulfur colloid, but will re-
main iso- or hypodense in both arterial and portal venous 
phases; this helps to distinguish RNH from FNH[74]. The 
use of  magnetic resonance imaging (MRI) to enhance 
diagnostic accuracy is still controversial. RNH lesions ap-
pear hyperintense on T1-weighted imaging and iso- or 
hypointense on T2 images (Figure 1). However, the sen-
sitivity and specificity are variable, according to a recent 
report[75].
RNH may be differentiated from large regenerative 
nodules (LRN) by either tomography or MRI. LRN can 
have a distinct presentation, and very often results in en-
hancing liver nodules, whereas RNH usually does not[76].
The spontaneous rupture of  the liver has also been 
reported in patients with SLE as a serious consequence 
related to the occurrence of  a large area of  infarction, 
due to a thrombotic phenomena of  the hepatic artery[77].
Focal disturbance of  the hepatic blood supply as-
sociated with lupus might also facilitates the hyperplastic 
development of  benign lesions in the liver, such as FNH 
and hemangiomas[78]. In a recent study analyzing a co-
hort of  35 SLE patients, FNH was observed at higher 
rates (5.7%) than in the normal population (0.6%-3.0%), 
and the same holds true for hemangiomas (54.2% vs 
0.4%-20% in the general adult population)[79]. Whereas 
FNH is thought to be part of  an abnormal adaptive 
regenerative response of  the liver parenchyma to local 
hemodynamic disturbances[80], hemangioma formation 
may be also favored by an increase of  angiogenic factors 
whose circulating levels are increased in SLE patients, 
such as estrogens[81], vascular endothelial growth factor, 
and interleukin-18[82,83]. Confirmation of  an increased in-
cidence of  these kinds of  hepatic benign lesions in SLE 
patients awaits large-scale studies.
Association of SLE with porphyria cutanea tarda
The association of  SLE with porphyria cutanea tarda 
(PCT), the most frequent type of  porphyria, is rare, and 
data defining whether this concomitance is pure coinci-
dence or true association are still lacking[84-86].
Common features in both diseases may be a confus-
ing factor. SLE is similar to PCT regarding photosensi-
tivity, but the presence of  blisters involving crusts and 
miliae in sun-exposed areas of  PCT patients, which is 
characteristic of  PCT but rare in SLE (< 5% of  the cas-
es)[87], can help to differentiate both diseases.
Co-existence of  PCT is usually associated with an-
Figure 1  Regenerative nodular hyperplasia.  A: Magnetic resonance image of RNH (axial T1 FSE). Note the two hyperintense, solid nodules localized in the right 
hepatic lobe (arrows); B: Typical findings of a RNH lesion revealed by reticulin staining to highlight the sinusoidal architecture of the liver. Note the liver sinusoidal 
shrinking, mimicking a pseudonodule. RNH: Regenerative nodular hyperplasia.
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timalarial drugs for treating lupus (e.g., chloroquine, hy-
droxychloroquine), and the regular use of  these drugs in 
SLE patients should be considered a risk for PCT. This 
usually represents a diagnostic problem, given the fre-
quent association of  PCT with a long list of  drugs apart 
from antimalarial agents, which makes the diagnosis of  
the cause even more complicated[88,89]. The risk associ-
ated with antimalarial drugs is dose-dependent; this is 
why several authors have contraindicated the daily intake 
of  these drugs for SLE due to the risk of  massive por-
phyrinuria, which is often associated with fever, nausea 
and hepatocelular injury, leading eventually to hepatic 
necrosis[78-81].
Association of SLE with drug-induced hepatotoxicity
Patients with SLE seem to have a relatively high rate 
of  drug-induced hepatotoxicity (Table 3). For example, 
Huang et al[90] reported 35 cases of  drug-induced hepato-
toxicity among 1533 SLE patients reviewed. In another 
study by Takahashi et al[18], liver damage could be ascribed 
to drug-induced liver injury in 31% from a total of  123 
SLE patients with overt liver dysfunction.
At the moment, it is impossible to know with cer-
tainty whether this high incidence is due to the chronic 
use, at relatively high doses, of  different drugs com-
monly prescribed to treat this disease, or whether there 
is any kind of  particular susceptibility that makes these 
patients prone to drug-induced hepatotoxicity. Of  note, 
SLE patients have been shown to have elevated levels 
of  systemic oxidative stress, which well correlated with 
liver enzyme elevations[91]. This relationship can be ten-
tatively explained by drug-induced oxidative stress in the 
liver of  these patients, with consequent liver injury. The 
elevated pro-oxidant liver status associated with a pro-
inflammatory conditions like SLE may also make the 
organ prone to develop hepatotoxicity by drugs exerting 
detrimental effects via oxidative mechanisms. Indeed, sev-
eral drugs used in autoimmune disease may themselves 
be converted into free radicals “in vivo”, thus aggravating 
oxidative damage[92,93]. Controlled, comparative studies 
on differential susceptibility to the same drug in patients 
with SLE and other autoimmune disease (e.g., rheumatoid 
arthritis) are lacking, but they would be useful to estab-
lish whether SLE is indeed a peculiar prone condition for 
drug-induced liver injury.
Around 80% of  SLE patients are treated with an-
algesic and NSAIDs, prescribed for febrile syndrome, 
athralgia/arthritis, serositis and/or cephale[94]. Hepatitis , 
fulminant hepatic failure, cholestasis, and mixed damage 
were reported to be caused by these compounds[95-98].
Lupus patients usually present a higher rate of  
NSAID-related complications than SLE-negative subjects. 
The most common complications are increased trans-
aminase levels, skin rashes triggered by sun, increased 
retention of  body fluids with arterial hypertension, gas-
tric ulcers, and aseptic meningitis. NSAIDs should not be 
indicated over the counter in SLE, and prescription must 
always be accompanied by recommendations related to 
strict clinical and laboratory vigilance[94].
For many years, aspirin was the most common drug 
associated with SLE-related liver damage. Increments 
of  ALT, AST and ALP have been reported in up to 25% 
of  the SLE patients consuming high doses of  aspirin (> 
2 g/d)[94].
In the early 70’s, the first publications appeared iden-
tifying aspirin as responsible for the hepatic damage in 
SLE patients[99,100]. It was not however until 1981 that 
Zimmerman, in a review focused on this issue, showed 
with certainty that aspirin generates both acute and 
chronic dose-dependent liver damage[101].
The onset of  aspirin-induced liver disease is marked 
by the appearance of  anorexia, nausea and non-specific 
pain in the upper abdomen. The patient usually does not 
present jaundice, and ALT and AST values are usually not 
more than 10 times ULN values. It is very common that 
AST levels are higher than ALT, and that these alterations 
are associated with normal ALP levels[102].
Although hepatotoxicity can occur with low levels of  
plasma salicylate, the mechanism is often dose-dependent, 
and the biochemical abnormalities revert when the drug 
is discontinued. In 3% of  the cases, the lesion can be se-
vere enough to lead to fatal hepatic failure. Chronic liver 
damage observed in the hepatic histology as a chronic 
active hepatitis pattern is much less common, and also 
returns to normality when the drug is withdrawn[103].
There is also controversial evidence that rheumatic 
patients usually have underlying conditions that increase 
the risk of  aspirin-induced hepatic failure. However, 
SLE-related hypoalbuminemia and juvenile rheumatoid 
arthritis are well documented risk factors as well[104-106].
Thiopurine analogues, such as azathriopine (AZA) 
and 5-mercaptopurine, are immunosuppressive drugs 
often employed in autoimmune diseases, including their 
Table 3  Hepatotoxicity induced by drugs used in lupus treat­
ment
Drug Liver injury and clinical significance
Corticosteroids Hepatomegalia
Fatty liver
NSAIDs Asymptomatic ALT increase
Hepatocellular, cholestatic, or mixed injury
ASA Acute and chronic hepatocellular injury
(resolve with withdrawal)
Methotrexate Asymptomatic ALT increase at high doses
Esteatosis, fibrosis, or cirrhosis
Anti-malarial drugs1 Rare hepatotoxic effects
Porphyria cutanea tarda
Azatioprine Cholestasis, peliosis, SOS, RNH
Thioguanine SOS, RNH, portal hypertension
Ciclophosphamide Rare case reports at conventional doses
SOS at high doses (resolve with dose reduction)
Mycophenolate mofetil Asymptomatic ALT increase
(resolve with dose reduction)
Rituximab No liver reactions have been reported
Belimumab No liver reactions have been reported
1Anti-malarial drugs: chloroquine, hydroxychloroquine. ALT: Alanine 
aminotransferase; NSAIDs: Non-steroidal antiinflamatory drugs; ASA: 
Acetylsalicilic acid; RNH: Nodular regenerative hyperplasia; SOS: Sinusoi-
dal obstruction syndrome.
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use to gain or maintain remission in SLE. Hepatotoxicity 
induced by thiopurine analogues occurs very often with 
increase in serum transaminase levels. It is associated 
generally with not severe liver injury, which responds to 
dose reduction in most patients. RNH is also a very rare 
but potentially severe complication of  thiopurine-based 
therapies. It is often asymptomatic, and neither biochemi-
cal nor molecular markers are indicative of  RNH. The 
suspicion should arise when there are clinical symptoms 
of  portal hypertension, increments of  transaminase lev-
els, or thrombocytopenia. A liver biopsy is essential in 
this case to confirm diagnosis[107].
A recent review by Musumba[108] reports that inflam-
matory bowel disease patients treated with AZA have a 
cumulative incidence of  RNH at 5 and 10 years of  0.6% 
and 1.3%, respectively, whereas those treated with high 
TG doses (> 40 mg/d) have an incidence of  RNH of  up 
to 62%; this rate is even higher in patients with elevated 
liver enzymes and/or thrombocytopenia, as compared 
with those lacking these abnormalities (76% vs 33%).
Methotrexate (MTX) is currently the first-line therapy 
for early and chronic rheumatic and psoriasic arthritis, 
but it is also indicated to symptomatic patients with 
SLE[109]. The recognition of  risk of  chronic liver dam-
age with MTX has prompted the need for intensive bio-
chemical monitoring from several decades ago onwards. 
The frequency of  hepatotoxicity varies widely according 
to differences in sampling, definitions of  damage, dose 
regimens, and presence of  other risk factors[110]. Although 
one study showed transaminase elevations higher than 
twice the upper limit of  normal in 13% of  patients[111], 
another report assessing 6000 patients receiving MTX, 
transaminase elevation was described in only 0.6% of  
patients[112]. Despite this wide difference, most studies 
concluded that prolonged use of  low-dose MTX mono-
therapy (10 mg/wk for 2-15 years) has favorable long-
term safety, and that the development of  significant liver 
fibrosis and cirrhosis is very low[113]; rather, steatosis was 
the main finding when biopsies were carried out for sur-
veillance dictated by cumulative MTX dose (Figure 2)[114]. 
Due to this disparity, Society’s guidelines differ on how 
patients on MTX should be monitored to prevent MTX-
induced liver fibrosis[115,116].
Although liver biopsy is still suggested in these pa-
tients in case of  persistent elevation of  transaminase 
after drug discontinuation, and for ruling out other 
potential cause of  chronic liver disease, there is robust 
evidence that Fibroscan Elastography may become in a 
near future the gold standard for fibrosis investigation in 
patients treated with MTX[117,118]. Most studies concluded 
that MTX therapy is safe, and that Fibroscan is useful 
for monitoring liver fibrosis in patients treated with this 
drug. Conclusions drawn from several studies indicate 
that severe liver fibrosis is a rare event in patients treated 
with MTX, and that it is probably unrelated to the dose. 
A recent work also studied the accuracy and feasibility 
of  Fibroscan and Fibrotest to detect MTX-induced liver 
fibrosis in 24 psoriasis patients[119]. The results obtained 
using Fibroscan and Fibrotest were compared with those 
obtained by liver histology. In this cohort, Fibrotest ac-
curately predicted the presence of  liver fibrosis, while 
Fibroscan accurately predicted the absence of  liver fibro-
sis in MTX users. These findings suggest that a combina-
tion of  approaches should prospectively be evaluated in 
monitoring and detecting significant MTX-induced liver 
fibrosis.
An association between MTX-induced toxicity and 
genetic polimorfism was suggested. Fisher et al[120] con-
ducted a meta-analysis of  published studies including 
1400 patients for association of  the C677T polymor-
phism of  the gene encoding methylene tetrahydrofo-
late reductase (MTHFR), and over 660 patients for the 
A1298C variant. They observed that the former but not 
the latter MTHFR gene variant was significantly related 
to MTX toxicity, including hepatotoxicity (OR = 1.71; 
CI: 1.32-2.21, P < 0.001). Despite results for MTHFR 
A
B
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Figure 2  (A) Macrosteatosis, (B) microsteatosis and (C) megamitochon-
dria (arrows), in a non-alcoholic 27-year-old patient with active systemic 
lupus erythematosus, treated with steroids and methotrexate (H and E 
staining).
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A1298C are not conclusive, C677T polymorphism ap-
pears to be a promising risk factor for the development 
of  low-dose-MTX-induced hepatotoxicity. Only few 
studies reported variants in genes that are predictive for 
MTX-induced hepatotoxicity[121].
Recent results showed that the administration of  met-
formin in rats receiving MTX normalized altered liver 
function tests and improved liver histopathological find-
ings. Therefore, this result suggests that this drug confers 
hepatoprotection against MTX-induced hepatotoxicity[122].
Minor abnormalities of  liver enzymes are relatively 
common when using anti-tumor necrosis factor (TNF) 
agents, such as infliximab, etanercept, and adalimumab, as 
anti-inflammatory and immunosuppressive compounds 
for the treatment of  autoimmune diseases[123,124]. Severe 
hepatic reactions are much less common, and include 
jaundice, hepatitis, cholestasis, and acute liver failure[125-127]. 
AIH is a rare, but increasingly recognized adverse event 
linked to treatments with anti-TNF agents[122]. In addition, 
lupus-like syndrome and anti-TNF-α-induced SLE were 
the most common disorders listed in a registry of  autoim-
mune diseases associated with anti-TNF-α agents[128,129]. 
Finally, rituximab is listed as able to reactivate HBV, even 
in patients with HBsAg negative and anti-HBsAg posi-
tive. This concept was recently reinforced by Seto et al[130], 
who reported a HBV reactivation rate of  24% in HBs 
Ag-negative, anti-HBc-positive patients undergoing ritux-
imab-based chemotherapy for hematologic malignancies, 
with most of  reactivations occurring during the first 6 
mo of  therapy. The Food and Drug Administration re-
cently announced the requirement of  a Boxed Warning 
for the anti-cancer immunosuppressive drugs Rituxan 
(rituximab). The Boxed Warning is specific for the risk 
of  HBV reactivation in patients who were previously in-
fected with the virus. Use of  these drugs in patients with 
previous HBV infection can result in severe liver damage 
if  the virus is reactivated[131].
Minocycline, a drug used in the treatment of  rheu-
matoid arthritis and acne, can induce a lupus-like syn-
drome[132]. In addition, statins, which inhibit hydroxy-
methylglutaryl-coenzyme A reductase, are widely used 
nowadays in SLE patients due to their immunomodulator 
and antiatherogenic effect. Several reports have sug-
gested that this drugs may also induce acute hepatitis and 
a lupus-like syndrome[133]. Finally, cyclophosphamide, 
an immunosuppressive and potent alkylating agent that 
improves the outcome of  major organ disease when ad-
ministered at high doses to SLE patients unresponsive to 
conventional therapy[134], was reported to induce hepa-
totoxicity associated with liver inflammation in isolated 
cases[135,136]. There is a report of  one case in the literature 
showing that this effect may occur even when the drug is 
administered at low doses[137].
CONCLUSION
Liver abnormalities is very common among patients 
with SLE, especially if  they are assessed from the bio-
chemical point of  view. It is generally asymptomatic, and 
frequently associated with steatosis, reactive unspecific 
changes and drug-related hepatotoxicity. Severe and pro-
gressive liver injury may occur, and even more often in 
the context of  a coexisting primary liver disease or dur-
ing pharmacotherapy.
SLE by itself  is not usually associated with aggres-
sive liver disease, but with an often asymptomatic entity 
referred to as “lupus hepatitis”, which is characterized by 
a mild increase in serum transaminase levels. However, 
there are overlapping profiles with other autoimmune 
disease, such as AIH and PBC, related to chronic and 
aggressive damage, sometimes accompanied by changes 
in immunological liver tests that help to establish an ac-
curate diagnosis. These overlap syndromes are thought to 
be variants of  an underlying general autoimmune disease, 
which shows up in a variable arrangement of  autoim-
mune disorders. An etiological role for anti-ribosomal P 
antibodies in triggering both lupus hepatitis and AIH has 
been proposed, but it remains uncertain and controversial.
SLE patients often present comorbility with non-
autoimmune liver diseases. They includes HCV, throm-
botic events in the splachnic vasculature, PCT, and drug-
induced hepatotoxicity, among others.
Hepatic circulation disorders may lead to adaptive 
parenchymal regenerative processes (e.g., RNH, FNH) or 
formation of  hemangiomas. RNH must be ruled out in 
all lupus patients who present evidence of  portal non-cir-
rhotic hypertension associated with hepatic pseudonodu-
lar images.
Drug-induced liver toxicity is also a common event 
in SLE, and may be ascribed to the chronic use, at high 
doses, of  medicines used to control the autoimmune 
disorder (e.g., thiopurine analogues, anti-TNF-α agents, 
statins, minocycline, cyclophosphamide) or to mitigate 
SLE symptoms (e.g., NSAIDs, MTX). SLE is an oxida-
tive-stress-prone condition, and the pro-oxidant effects 
of  many of  these drugs may be a causal factor.
Due to the relatively frequent multifaceted manifesta-
tions of  liver diseases in SLE, with an often difficult dif-
ferential diagnosis each others, an assessment of  immu-
nological, serological and virological markers should be 
systematically carried out in patients with elevated levels 
of  liver enzymes. Testing for AMA, ASMA, and HCV 
may be particularly helpful. In addition, an analysis of  the 
patient’s medical history so as to have an accurate record 
of  the drugs taken by the patient should be carefully 
done. Finally, histology is in some cases the only reliable 
method of  diagnosis, and should be carried out accord-
ingly. We hope the information provided by this review 
helps to systematize the knowledge of  the field, so as to 
make the challenge of  identifying liver diseases associated 
with SLE more approachable to the clinician.
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